Loading...
Docoh

Merus (MRUS)

Press releases

From Benzinga Pro
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
9 May 22
Earnings, Health Care, Press Releases
- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host investor call on Sunday, June 5 at 6:00 p.m. CT- Clinical data
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
27 Apr 22
News, Health Care, Press Releases
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length
Merus Announces Publication in Nature Cancer on Petosemtamab's (MCLA-158) Unique Mechanism of Action
25 Apr 22
Press Releases
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length
Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting
8 Mar 22
News, Press Releases
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
28 Feb 22
Earnings, Press Releases
As of February 2022, more than 100 patients with NRG1 gene fusion positive ("NRG1+") cancer have been treated with zenocutuzumab ("Zeno") monotherapy Clinical data updates planned for lead program Zeno in 1H22 and for